BGI Genomics Co., Ltd. (300676)
Market Closed
10 Aug, 06:57
XSHE XSHE Primary ¥
40. 69
+0.73
+1.8268%
¥
19.47B Market Cap
- P/E Ratio
0.4% Div Yield
14.88M Volume
- Eps
¥ 39.96
Previous Close Want to track 300676 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
300676 closed today higher at ¥40.69, an increase of 1.8268% from yesterday's close, completing a monthly increase of 15.6294% or ¥5.5. Over the past 12 months, 300676 stock lost -10.2756%.
300676 is not paying dividends to its shareholders.
The last earnings report, released on May 09, 2025, missed the consensus estimates by -0.1278%. On average, the company has fell short of earnings expectations by -0.1476%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
300676 Chart
BGI Genomics Co., Ltd. (300676) FAQ
What is the stock price today?
The current price is ¥40.69.
On which exchange is it traded?
BGI Genomics Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 300676.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.4%.
What is its market cap?
As of today, the market cap is 19.47B.
Has BGI Genomics Co., Ltd. ever had a stock split?
No, there has never been a stock split.
BGI Genomics Co., Ltd. Profile
| Professional Services Industry | Industrials Sector | Mr. Lijian Zhao CEO | XSHE Exchange | CNE100003449 ISIN |
| China Country | 3,702 Employees | 4 Jul 2024 Last Dividend | - Last Split | - IPO Date |
Overview
BGI Genomics Co., Ltd., a leader in sequencing services and genetic testing, operates both within China and on an international scale, catering to medical institutions, research entities, and various public and private partners. With roots stretching back to its inception in 1999 and originating as Shenzhen BGI Medicine Co., Ltd., the company underwent a rebranding to its current name in 2015. The heart of its operations lies in Shenzhen, China, where it continues to push the boundaries of genomics and related research fields.
Products and Services
- DNA, RNA, and Customized Sequencing Services: BGI provides comprehensive sequencing solutions tailored to meet the diverse needs of research and medical communities. This includes high-throughput DNA sequencing, RNA sequencing, and bespoke options designed for specific project requirements.
- Non-Invasive Prenatal Testing (NIPT): Offering a safer approach for expectant mothers, BGI's NIPT services detect potential genetic disorders in fetuses without posing risks associated with invasive testing methods.
- Reproductive Health Screening: This service encompasses a spectrum of genetic tests aimed at identifying risks before or during pregnancy, aiding in informed family planning and management of reproductive health.
- Newborn Genetic Screening: To ensure early intervention, BGI's newborn screening detects genetic conditions soon after birth, facilitating timely treatment to mitigate long-term effects.
- Clinical Exome Sequencing: Focused on the exome, this service helps uncover genetic variants responsible for complex diseases, supporting both diagnosis and personalized medicine.
- Oncology Solutions: BGI's comprehensive suite for cancer research and clinical applications includes both diagnostic services and research tools, enabling cutting-edge cancer genomics studies.
- COVID-19 Solutions: In response to the pandemic, BGI developed diagnostic and research tools including laboratory solutions for patient detection, IgM and IgG antibody detection kits, and RT-PCR kits for identifying SARS-CoV-2 infections.
In addition, BGI extends its expertise across various research domains such as agriculture, food science, metagenomics, biomarker discovery, and drug research, showcasing its versatile capabilities in advancing genomics for the betterment of society.
Contact Information
Address: Building NO.7
Phone: 86 400 706 6615
Website: https://www.bgi.com
